Assessment the effect of zinc supplementation on adverse outcomes of pregnancy

Assessment the effect of zinc supplementation on adverse outcomes of pregnancy, a Randomized Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138707161306N1

Enrollment

500

Registered

2010-04-26

Start date

2009-03-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse outcomes of pregnancy. Fetus and newborn affected by maternal nutritional disorders

Interventions

Intervention 1: zinc 30 mg from 12th week of gestetion every other day in intervention group. Intervention 2: no intervention in control group.

Treatment - Drugs

zinc 30 mg from 12th week of gestetion every other day in intervention group

no intervention in control group

Eligibility

Sex/Gender

Female

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Gestetional age of 12-16 weeks based on reliable LMP or first trimester ultrasound, lack of history of high risk pregnancy, lack of chronic underlying diseases (such as heart disease HTN, DM). Exclusion criteria: lack of complete treatment or lack of follow-up

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Congenital defect. Timepoint: postpartum. Method of measurement: neonatal examination.;Birth weight. Timepoint: postpartum. Method of measurement: neonatal weighting.;Preterm labour rate. Timepoint: postpartum. Method of measurement: documented data.;Preeclampsia rate. Timepoint: postpartum. Method of measurement: control of blood pressure.;Chorioamnionitis rate. Timepoint: postpartum. Method of measurement: examination.;Neonatal infection rate. Timepoint: postpartum. Method of measurement: examination.;Postpartum infection rate. Timepoint: postpartum. Method of measurement: examination.;Postpartum hemorrhage rate. Timepoint: postpartum. Method of measurement: examination.;Still birth rate. Timepoint: postpartum. Method of measurement: examination.	—

Measure

Time frame

Congenital defect. Timepoint: postpartum. Method of measurement: neonatal examination.;Birth weight. Timepoint: postpartum. Method of measurement: neonatal weighting.;Preterm labour rate. Timepoint: postpartum. Method of measurement: documented data.;Preeclampsia rate. Timepoint: postpartum. Method of measurement: control of blood pressure.;Chorioamnionitis rate. Timepoint: postpartum. Method of measurement: examination.;Neonatal infection rate. Timepoint: postpartum. Method of measurement: examination.;Postpartum infection rate. Timepoint: postpartum. Method of measurement: examination.;Postpartum hemorrhage rate. Timepoint: postpartum. Method of measurement: examination.;Still birth rate. Timepoint: postpartum. Method of measurement: examination.

—

Secondary

Measure	Time frame
Apgar score of 1st , 5th minute. Timepoint: postpartum. Method of measurement: examination.;Duration of pregnancy. Timepoint: postpartum. Method of measurement: documanted data.;Neonatal Antropometric measures. Timepoint: postpartum. Method of measurement: examination.;Wieght gain during pregnancy. Timepoint: postpartum. Method of measurement: weighting.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026